Scholarly Works - Book sections
Book section
·
January 1, 2023
Advancements in hematopoietic cell transplantation (HCT) have been associated with expanding indications and eligibility, alternative donor options, and improvement in overall survival. Yet, HCT for hematologic malignancies are still associated with the po ...
Full text
Cite
Book section
·
January 1, 2021
Although potentially curative therapy, hematopoietic cell transplantation (HCT) is fraught with many unique and life-threatening complications. Pulmonary complications, both infectious and noninfectious, are common and a significant source of nonrelapse mo ...
Full text
Cite
Book section
·
January 1, 2020
Chimeric antigen receptor (CAR) T-cells belong to the class of immune effector cell (IEC) therapies, which have been associated with striking clinical outcomes, particularly among patients with relapsed/refractory hematologic malignancies. Yet, they have a ...
Full text
Cite
Book section
·
October 12, 2019
In 2017, the US Food and Drug Administration (FDA) approved a form of cancer immunotherapy, specifically, a chimeric antigen receptor (CAR), for the treatment of pediatric and young adult patients with refractory CD19-positive B-cell precursor acute lympho ...
Full text
Cite
Book section
·
January 1, 2019
Hematopoietic cell transplantation (HCT) and cellular therapy (CT) are potentially lifesaving treatments for children with malignant and nonmalignant diseases. Advancements in care have led to expanding patient eligibility, with overall reduced morbidity a ...
Full text
Cite
